We are pleased to announce that Zencore Biologics has recently obtained its first “Drug Production License” (Type-C Certificate), marking a significant milestone for the company in the field of biopharmaceutical CDMO.Notably, this is the first ADC drug production license issued to a CDMO in Shanghai granted by the Municipal Drug Administration.We are honored to be the first company in Shanghai to receive this certificate, which fully reflects our technical capabilities, commitment, and industry leadership.

Zencore Biologics Compliance Engineer Xu Hu (left), CEO Assistant and Vice President of Operations Yixin Li (center), and Compliance Head Zhengming Cao (right).

Throughout the process of obtaining this license, Zencore Biologics demonstrated outstanding technical capabilities and a rigorous quality management system. This achievement not only recognizes the hard work and perseverance of our team but also serves as a testament to the trust placed in us by our clients, partners, and investors. Furthermore, the acquisition of this license lays a solid foundation for our commercial production and enhances our ability to provide our clients with “One-Stop Service,” covering everything from amino acid sequences to commercial manufacturing within the drug development life cycle.

With the attainment of this significant milestone, Zencore will continue to uphold its core values of "Pursue the Truth, Commit to the Utmost, Strive for Excellence" for our global biopharmaceutical clients. We aim to contribute to the creation of quality and affordable medicines for patients by leveraging our established technology platform and facilities.We look forward to working hand-in-hand with our clients and partners to contribute to a healthier world.